Glutamate in schizophrenia: clinical and research implications

Schizophrenia Research
D C Goff, L Wine

Abstract

The excitatory amino acids, glutamate and aspartate, are of interest to schizophrenia research because of their roles in neurodevelopment, neurotoxicity and neurotransmission. Recent evidence suggests that densities of glutamatergic receptors and the ratios of subunits composing these receptors may be altered in schizophrenia, although it is unclear whether these changes are primary or compensatory. Agents acting at the phencyclidine binding site of the NMDA receptor produce symptoms of schizophrenia in normal subjects, and precipitate relapse in patients with schizophrenia. The improvement of negative symptoms with agents acting at the glycine modulatory site of the NMDA receptor, as well as preliminary evidence that clozapine may differ from conventional neuroleptic agents in its effects on glutamatergic systems, suggest that clinical implications may follow from this model. While geriatric patients may be at increased risk for glutamate-mediated neurotoxicity, very little is known about the specific relevance of this model to geriatric patients with schizophrenia.

References

Oct 20, 1992·European Journal of Pharmacology·J F FloodT H Lanthorn
Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Dec 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·J Collinge, D Curtis
Jun 1, 1991·Clinical Neuropharmacology·R B RosseS I Deutsch
Aug 1, 1990·Clinical Neuropharmacology·R B RosseS I Deutsch
Apr 1, 1990·Psychiatry Research·F MacciardiE Smeraldi
Jan 1, 1990·Brain Research. Brain Research Reviews·J W McDonald, M V Johnston
Feb 1, 1990·Journal of Clinical Psychopharmacology·J CostaS G Potkin
Sep 1, 1985·The British Journal of Psychiatry : the Journal of Mental Science·L BjerkenstedtF A Wiesel
Dec 1, 1989·Pharmacology, Biochemistry, and Behavior·G E HandelmannA A Cordi
Feb 1, 1989·Clinical Neuropharmacology·S I DeutschJ M Morihisa
Jun 1, 1989·Journal of Neurochemistry·J F DeakinA J Cross
Aug 1, 1989·Neuron·L O Trussell, G D Fischbach
Nov 1, 1989·Psychiatry Research·B KirkpatrickW T Carpenter
Apr 1, 1987·Psychiatry Research·E R KorpiD R Weinberger
Jan 15, 1988·Biological Psychiatry·R Waziri
Jan 1, 1970·Comprehensive Psychiatry·J SimeonD Ponce
Jan 1, 1982·Archiv für Psychiatrie und Nervenkrankheiten·W F GattazH Beckmann
Oct 10, 1983·Neuroscience Letters·T NishikawaM Toru
Dec 1, 1995·Archives of General Psychiatry·J W Olney, N B Farber
Aug 1, 1993·Trends in Pharmacological Sciences·P H Seeburg

❮ Previous
Next ❯

Citations

Aug 27, 1999·Journal of Neuroscience Research·X ZhangA A Boulton
Oct 1, 2008·Indian Journal of Clinical Biochemistry : IJCB·N GaurS Mishra
Jun 22, 1999·Biological Psychiatry·A G CardnoM C O'Donovan
Feb 1, 2003·Pharmacology & Therapeutics·Christine Konradi, Stephan Heckers
Sep 30, 2000·Brain Research. Brain Research Reviews·P C MoserP M Moran
Sep 23, 2003·Brain Research. Brain Research Reviews·Michael S Lidow
Apr 21, 1999·Brain Research. Brain Research Reviews·G E DuncanJ A Lieberman
Dec 15, 2000·Progress in Neurobiology·T M Tzschentke
Dec 17, 2002·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·H TapieroK D Tew
Apr 6, 2001·Clinical Neuropharmacology·S I DeutschJ Mastropaolo
May 17, 2005·BMC Psychiatry·Nadine NortonMichael J Owen
Aug 28, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jonathan KipnisMichal Schwartz
Feb 13, 2016·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·M Seifi, J D Swinny
Oct 22, 2008·Psychiatry Research·Do-Hyung KangJun Soo Kwon
Feb 17, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·H Serdar GergerliogluMehmet Yumru
Apr 12, 2005·Schizophrenia Research·Emile G BruneauJames H Meador-Woodruff
Dec 23, 2003·The European Journal of Neuroscience·S A BrodyM A Geyer
Sep 4, 2012·Psychiatry Research·Jun-Ming LiChia-Hsiang Chen
Dec 21, 2012·Neuroscience and Biobehavioral Reviews·Natalie Matosin, Kelly A Newell
May 3, 2000·Medical Hypotheses·D R Lara, D O Souza
Jun 15, 2011·Journal of Pharmacological Sciences·Eiichi Hinoi, Yukio Yoneda
Jan 5, 2010·Psychiatry Investigation·Vincenzo De LucaMarcellino Monda
Apr 1, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sarah M Clinton, James H Meador-Woodruff
Jan 1, 2012·Biomolecules & Therapeutics·Maria D RubioJames H Meador-Woodruff
Jan 11, 2020·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Robert A McCutcheonOliver D Howes
Dec 23, 2003·European Journal of Biochemistry·Eiichi HinoiYukio Yoneda
Oct 16, 2001·Biological Psychiatry·R SchwarczR C Roberts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
C GrayD Attwell
The American Journal of Psychiatry
Husseini Manji
© 2021 Meta ULC. All rights reserved